Insider Sale Sends Glaukos Down 13% Despite Positive Epioxa Data
GKOS has more than doubled off its 52-week low of $73.16.
Summary
Glaukos shares fell over 13% on Thursday after CDO Tomas Navratil sold $251K in stock at $163.93-$165.60, overshadowing positive three-year Epioxa extension data and a new RevOpsis licensing deal. The sale, executed under a 10b5-1 plan adopted June 12, reduced Navratil's stake by nearly 2% to 69,291 shares. This follows a pattern of insider selling, including a $2.48M sale by Navratil in August and a $10.8M planned sale by officer Joseph Gilliam. The market reaction suggests investors are weighing insider conviction against the company's strong pipeline momentum.
At the time of this announcement, GKOS was trading at $153.16 on NYSE in the Life Sciences sector, with a market capitalization of approximately $9B. The 52-week trading range was $73.16 to $191.62. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.